Implications of glucocorticoid therapy in idiopathic inflammatory myopathies

Nature Reviews Rheumatology

Volumn 8, Issue 8, 2012, Pages 448-457

  Hanaoka, Beatriz Y ^a   Peterson, Charlotte A ^b   Horbinski, Craig ^a   Crofford, Leslie J ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ENOBOSARM; F BOX ONLY PROTEIN 40; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KRUPPEL LIKE FACTOR; KRUPPEL LIKE FACTOR 15; MUSCLE RING FINGER 1 PROTEIN; MYOD PROTEIN; PLACEBO; SOMATOMEDIN C; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CATABOLISM; CORTICOSTEROID THERAPY; CRITICAL ILLNESS; CUSHING SYNDROME; DOSE RESPONSE; DRUG BINDING; DRUG DOSE INCREASE; DRUG EFFECT; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; ECCHYMOSIS; HUMAN; IDIOPATHIC DISEASE; IMMUNE DYSREGULATION; LEG EDEMA; MACROPHAGE ACTIVATION; MUSCLE ATROPHY; MUSCLE METABOLISM; MUSCLE NECROSIS; MUSCLE REGENERATION; MYCOSIS; MYOSITIS; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SKIN DISEASE; SLEEP DISORDER;

DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; HUMANS; IMMUNE SYSTEM; MUSCLE WEAKNESS; MUSCLE, SKELETAL; MYOSITIS; REGENERATION; TREATMENT OUTCOME;

EID: 84864580655     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2012.85     Document Type: Review

References (95)

1. Bronner, I. M. et al. Long-term outcome in polymyositis and dermatomyositis. Ann. Rheum. Dis. 65, 1456-1461 (2006
2. Ng, K. P., Ramos, F., Sultan, S. M. and Isenberg, D. A. Concomitant diseases in a cohort of patients with idiopathic myositis during long-term follow-up. Clin. Rheumatol. 28, 947-953 (2009
3. Clarke, A. E., Bloch, D. A., Medsger, T. A. Jr and Oddis, C. V. A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis. Arthritis Rheum. 38, 1218-1224 (1995
4. Sultan, S. M., Ioannou, Y., Moss, K. and Isenberg, D. A. Outcome in patients with idiopathic inflammatory myositis: Morbidity and mortality. Rheumatology (Oxford) 41, 22-26 (2002
5. Ponyi, A. et al. Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis. Rheumatology (Oxford) 44, 83-88 (2005
6. Beaulieu, E. and Morand, E. F. Role of GILZ in immune regulation, glucocorticoid actions and rheumatoid arthritis. Nat. Rev. Rheumatol. 7, 340-348 (2011
7. Stahn, C. and Buttgereit, F. Genomic and nongenomic effects of glucocorticoids. Nat. Clin. Pract. Rheumatol. 4, 525-533 (2008
8. Schacke, H. et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc. Natl Acad. Sci. USA 101, 227-232 (2004
9. Metselaar, J. M., Wauben, M. H., Wagenaar-Hilbers, J. P., Boerman, O. C. and Storm, G. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum. 48, 2059-2066 (2003
10. Buttgereit, F. et al. Targeting pathophysiological rhythms: Prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann. Rheum. Dis. 69, 1275-1280 (2010
11. Fardet, L., Cabane, J., Lebbe, C., Morel, P. and Flahault, A. Incidence and risk factors for corticosteroid-induced lipodystrophy: A prospective study. J. Am. Acad. Dermatol. 57, 604-609 (2007
12. Sarnes, E. et al. Incidence and US costs of corticosteroid-associated adverse events: A systematic literature review. Clin. Ther. 33, 1413-1432 (2011
13. Cooper, M. S. Sensitivity of bone to glucocorticoids. Clin. Sci. (Lond.) 107, 111-123 (2004
14. French, D. et al. A PAI 1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: A report from the Children's Oncology Group. Blood 111, 4496-4499 (2008
15. Bond, J. et al. Polymorphism in the PAI 1 (SERPINE1) gene and the risk of osteonecrosis in children with acute lymphoblastic leukemia. Blood 118, 2632-2633 (2011
16. van Rossum, E. F. and Lamberts, S. W. Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Recent Prog. Horm. Res. 59, 333-357 (2004
17. Trementino, L. et al. Association of glucocorticoid receptor polymorphism A3669G with decreased risk of developing diabetes in patients with Cushing's syndrome. Eur. J. Endocrinol. 166, 35-42 (2012
18. Stahn, C., Lowenberg, M., Hommes, D. W. and Buttgereit, F. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol. Cell. Endocrinol. 275, 71-78 (2007
19. Buttgereit, F., Straub, R. H., Wehling, M. and Burmester, G. R. Glucocorticoids in the treatment of rheumatic diseases: An update on the mechanisms of action. Arthritis Rheum. 50, 3408-3417 (2004
20. Lowenberg, M. et al. Rapid immunosuppressive effects of glucocorticoids mediated through Lck and Fyn. Blood 106, 1703-1710 (2005
21. Croxtall, J. D., Choudhury, Q. and Flower, R. J. Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. Br. J. Pharmacol. 130, 289-298 (2000
22. Reichardt, H. M. et al. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J. 20, 7168-7173 (2001
23. Almawi, W. Y. and Melemedjian, O. K. Molecular mechanisms of glucocorticoid antiproliferative effects: Antagonism of transcription factor activity by glucocorticoid receptor. J. Leukoc. Biol. 71, 9-15 (2002
24. De Bosscher, K., Vanden Berghe, W. and Haegeman, G. The interplay between the glucocorticoid receptor and nuclear factor-κB or activator protein 1: Molecular mechanisms for gene repression. Endocr. Rev. 24, 488-522 (2003
25. Auphan, N., DiDonato, J. A., Rosette, C., Helmberg, A. and Karin, M. Immunosuppression by glucocorticoids: Inhibition of NF κB activity through induction of IκB synthesis. Science 270, 286-290 (1995
26. Rhen, T. and Cidlowski, J. A. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N. Engl. J. Med. 353, 1711-1723 (2005
27. Huscher, D. et al. Dose-related patterns of glucocorticoid-induced side effects. Ann. Rheum. Dis. 68, 1119-1124 (2009
28. Mizuno, H. et al. Glucocorticoid induced the expression of mRNA and the secretion of lipocortin 1 in rat astrocytoma cells. Brain Res. 746, 256-264 (1997
29. Hasselgren, P. O. Glucocorticoids and muscle catabolism. Curr. Opin. Clin. Nutr. Metab. Care 2, 201-205 (1999
30. Tiao, G. et al. Energy ubiquitin dependent muscle proteolysis during sepsis in rats is regulated by glucocorticoids. J. Clin. Invest. 97, 339-348 (1996
31. Rannels, S. R., Rannels, D. E., Pegg, A. E. and Jefferson, L. S. Glucocorticoid effects on peptide-chain initiation in skeletal muscle and heart. Am. J. Physiol. 235, E134-E139 (1978
32. Schacke, H., Docke, W. D. and Asadullah, K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 96, 23-43 (2002
33. Menconi, M. et al. Role of glucocorticoids in the molecular regulation of muscle wasting. Crit. Care Med. 35, S602-608 (2007
34. Imae, M., Fu, Z., Yoshida, A., Noguchi, T. and Kato, H. Nutritional and hormonal factors control the gene expression of FoxOs, the mammalian homologues of DAF 16. J. Mol. Endocrinol. 30, 253-262 (2003
35. Gustafsson, T. et al. Effects of 3 days unloading on molecular regulators of muscle size in humans. J. Appl. Physiol. 109, 721-727 (2010
36. Menconi, M., Gonnella, P., Petkova, V., Lecker, S. and Hasselgren, P. O. Dexamethasone and corticosterone induce similar, but not identical, muscle wasting responses in cultured L6 and C2C12 myotubes. J. Cell. Biochem. 105, 353-364 (2008
37. Glass, D. J. Signaling pathways perturbing muscle mass. Curr. Opin. Clin. Nutr. Metab. Care 13, 225-229 (2010
38. Shi, J., Luo, L., Eash, J., Ibebunjo, C. and Glass, D. J. The SCF-Fbxo40 complex induces IRS1 ubiquitination in skeletal muscle, limiting IGF1 signaling. Dev. Cell 21, 835-847 (2011
39. Wang, X., Hu, Z., Hu, J., Du, J. and Mitch, W. E. Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology 147, 4160-4168 (2006
40. Hasselgren, P. O. and Fischer, J. E. Counter-regulatory hormones and mechanisms in amino acid metabolism with special reference to the catabolic response in skeletal muscle. Curr. Opin. Clin. Nutr. Metab. Care 2, 9-14 (1999
41. Rennie, M. J., Tadros, L., Khogali, S., Ahmed, A. and Taylor, P. M. Glutamine transport and its metabolic effects. J. Nutr. 124, (Suppl.) 1503S-1508S (1994
42. Schakman, O. et al. Role of Akt/GSK-3β/β-catenin transduction pathway in the muscle anti-atrophy action of insulin-like growth factor I in glucocorticoid-treated rats. Endocrinology 149, 3900-3908 (2008
43. Wang, H., Kubica, N., Ellisen, L. W., Jefferson, L. S. and Kimball, S. R. Dexamethasone represses signaling through the mammalian target of rapamycin in muscle cells by enhancing expression of REDD1. J. Biol. Chem. 281, 39128-39134 (2006
44. Shimizu, N. et al. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab 13, 170-182 (2011
45. Ma, K. et al. Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am. J. Physiol. Endocrinol. Metab. 285, E363-E371 (2003
46. Amirouche, A. et al. Down-regulation of Akt/mammalian target of rapamycin signaling pathway in response to myostatin overexpression in skeletal muscle. Endocrinology 150, 286-294 (2009
47. Nagaraju, K. et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: Potential role in muscle fiber damage and dysfunction. Arthritis Rheum. 52, 1824-1835 (2005
48. Ladner, K. J., Caligiuri, M. A. and Guttridge, D. C. Tumor necrosis factor-regulated biphasic activation of NF κB is required for cytokine-induced loss of skeletal muscle gene products. J. Biol. Chem. 278, 2294-2303 (2003
49. Cai, D. et al. IKKβ/NF-κB activation causes severe muscle wasting in mice. Cell 119, 285-298 (2004
50. Oeckinghaus, A., Hayden, M. S. and Ghosh, S. Crosstalk in NF κB signaling pathways. Nat. Immunol. 12, 695-708 (2011
51. Scheinman, R. I., Cogswell, P. C., Lofquist, A. K. and Baldwin, A. S. Jr. Role of transcriptional activation of I κ B a in mediation of immunosuppression by glucocorticoids. Science 270, 283-286 (1995
52. De Bosscher, K. et al. Glucocorticoid-mediated repression of nuclear factor κB dependent transcription involves direct interference with transactivation. Proc. Natl Acad. Sci. USA 94, 13504-13509 (1997
53. De Bosscher, K. et al. Glucocorticoids repress NF κB driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc. Natl Acad. Sci. USA 97, 3919-3924 (2000
54. Bakkar, N. and Guttridge, D. C. NF κB signaling: A tale of two pathways in skeletal myogenesis. Physiol. Rev. 90, 495-511 (2010
55. Maneechotesuwan, K., Ekjiratrakul, W., Kasetsinsombat, K., Wongkajornsilp, A. and Barnes, P. J. Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3 dioxygenase. J. Allergy Clin. Immunol. 126, 754-762 e751 (2010
56. Kamei, Y. et al. Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. J. Biol. Chem. 279, 41114-41123 (2004
57. Hasselgren, P. O. et al. Corticosteroids and muscle wasting: Role of transcription factors, nuclear cofactors, and hyperacetylation. Curr. Opin. Clin. Nutr. Metab. Care 13, 423-428 (2010
58. Adams, C. M. Role of the transcription factor ATF4 in the anabolic actions of insulin and the anti-anabolic actions of glucocorticoids. J. Biol. Chem. 282, 16744-16753 (2007
59. Ebert, S. M. et al. The transcription factor ATF4 promotes skeletal myofiber atrophy during fasting. Mol. Endocrinol. 24, 790-799 (2010
60. Dastmalchi, M. et al. Effect of physical training on the proportion of slow-twitch type I muscle fibers, a novel nonimmune-mediated mechanism for muscle impairment in polymyositis or dermatomyositis. Arthritis Rheum. 57, 1303-1310 (2007
61. Loell, I. et al. Higher proportion of fast-twitch (type II) muscle fibres in idiopathic inflammatory myopathies-evident in chronic but not in untreated newly diagnosed patients. Clin. Physiol. Funct. Imaging 31, 18-25 (2011
62. Amato, A. A. and Russell, J. A. Neuromuscular Disorders (McGraw-Hill, New York, 2008
63. Dubois, E. L. Systemic lupus erythematosus; results of treatment with triamcinolone. Calif. Med. 89, 195-203 (1958
64. Pereira, R. M. and Freire de Carvalho, J. Glucocorticoid-induced myopathy. Joint Bone Spine 78, 41-44 (2011
65. Dekhuijzen, P. N. et al. Corticosteroid treatment and nutritional deprivation cause a different pattern of atrophy in rat diaphragm. J. Appl. Physiol. 78, 629-637 (1995
66. Shee, C. D. Risk factors for hydrocortisone myopathy in acute severe asthma. Respir. Med. 84, 229-233 (1990
67. MacFarlane, I. A. and Rosenthal, F. D. Severe myopathy after status asthmaticus. Lancet 2, 615 (1977
68. Hirano, M. et al. Acute quadriplegic myopathy: A complication of treatment with steroids, nondepolarizing blocking agents, or both. Neurology 42, 2082-2087 (1992
69. Larsson, L. et al. Acute quadriplegia and loss of muscle myosin in patients treated with nondepolarizing neuromuscular blocking agents and corticosteroids: Mechanisms at the cellular and molecular levels. Crit. Care Med. 28, 34-45 (2000
70. Latronico, N. and Bolton, C. F. Critical illness polyneuropathy and myopathy: A major cause of muscle weakness and paralysis. Lancet Neurol. 10, 931-941 (2011
71. Dhand, U. K. Clinical approach to the weak patient in the intensive care unit. Respir. Care 51, 1024-1040; discussion 1040-1021 (2006
72. Berger, A. M., Shuster, J. L. and von Roenn, A. H. Principles and Practice of Palliative Care and Supportive Oncology (Lippincott Williams and Wilkins, Philadelphia, 2007
73. Lacomis, D., Petrella, J. T. and Giuliani, M. J. Causes of neuromuscular weakness in the intensive care unit: A study of ninety-two patients. Muscle Nerve 21, 610-617 (1998
74. Holterman, C. E. and Rudnicki, M. A. Molecular regulation of satellite cell function. Semin. Cell. Dev. Biol. 16, 575-584 (2005
75. Tsivitse, S. Notch and Wnt signaling, physiological stimuli and postnatal myogenesis. Int. J. Biol. Sci. 6, 268-281 (2010
76. Sun, L., Trausch-Azar, J. S., Muglia, L. J. and Schwartz, A. L. Glucocorticoids differentially regulate degradation of MyoD and Id1 by N terminal ubiquitination to promote muscle protein catabolism. Proc. Natl Acad. Sci. USA 105, 3339-3344 (2008
77. Schakman, O., Gilson, H., Kalista, S. and Thissen, J. P. Mechanisms of muscle atrophy induced by glucocorticoids. Horm. Res. 72 (Suppl. 1), 36-41 (2009
78. Jogo, M., Shiraishi, S. and Tamura, T. A. Identification of MAFbx as a myogenin-engaged F box protein in SCF ubiquitin ligase. FEBS Lett. 583, 2715-2719 (2009
79. Dale, D. C., Boxer, L. and Liles, W. C. The phagocytes: Neutrophils and monocytes. Blood 112, 935-945 (2008
80. Tidball, J. G. and Villalta, S. A. Regulatory interactions between muscle and the immune system during muscle regeneration. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298, R1173-R1187 (2010
81. Dumont, N. and Frenette, J. Macrophages protect against muscle atrophy and promote muscle recovery in vivo and in vitro: A mechanism partly dependent on the insulin-like growth factor 1 signaling molecule. Am. J. Pathol. 176, 2228-2235 (2010
82. Tidball, J. G. and Wehling-Henricks, M. Macrophages promote muscle membrane repair and muscle fibre growth and regeneration during modified muscle loading in mice in vivo. J. Physiol. 578, 327-336 (2007
83. Przybyla, B. et al. Aging alters macrophage properties in human skeletal muscle both at rest and in response to acute resistance exercise. Exp. Gerontol. 41, 320-327 (2006
84. Gordon, S. and Taylor, P. R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5, 953-964 (2005
85. Gordon, S. Alternative activation of macrophages. Nat. Rev. Immunol. 3, 23-35 (2003
86. Ruffell, D. et al. A CREB C/EBPβ cascade induces M2 macrophage-specific gene expression and promotes muscle injury repair. Proc. Natl Acad. Sci. USA 106, 17475-17480 (2009
87. Newton, R. Molecular mechanisms of glucocorticoid action: What is important? Thorax 55, 603-613 (2000
88. Jones, A., Hwang, D. J., Narayanan, R., Miller, D. D. and Dalton, J. T. Effects of a novel selective androgen receptor modulator on dexamethasone- induced and hypogonadism-induced muscle atrophy. Endocrinology 151, 3706-3719 (2010
89. Dalton, J. T. et al. The selective androgen receptor modulator GTx 024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: Results of a double-blind, placebo-controlled phase II trial. J. Cachexia Sarcopenia Muscle 2, 153-161 (2011
90. Adcock, I. M. and Caramori, G. Cross-talk between pro-inflammatory transcription factors and glucocorticoids. Immunol. Cell Biol. 79, 376-384 (2001
91. McMaster, A. and Ray, D. W. Drug insight: Selective agonists and antagonists of the glucocorticoid receptor, (2008
92. Wang, H. et al. NF κB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. Mol. Cell. Biol. 27, 4374-4387 (2007
93. Castets, P. et al. Satellite cell loss and impaired muscle regeneration in selenoprotein N deficiency. Hum. Mol. Genet. 20, 694-704 (2011
94. Ge, Y. et al. mTOR regulates skeletal muscle regeneration in vivo through kinase-dependent and kinase-independent mechanisms. Am. J. Physiol. Cell. Physiol. 297, C1434-C1444 (2009
95. Wagers, A. J. and Conboy, I. M. Cellular and molecular signatures of muscle regeneration: Current concepts and controversies in adult myogenesis. Cell 122, 659-667 (2005